

Drug Industry Analyst Forecast

This guide explains where to find Industry Analyst Forecasts to evaluate sales expectations in upcoming years for drugs of interest.

Industry Analyst Forecasts are available for the most important drugs in late clinical trials or higher phases of development in a given franchise. Refinitiv, Clarivate's business partner, provides this information as calculated by brokers and financial analysts. Cortellis offers individual and consensus forecasts in drug reports for more than 1,500 drugs.

Example: Evaluate Industry Analyst Forecast for *lebrikizumab* over the next 3 years.

1. Quick search the drug name at the top and select **'Index'**.




2. Click the **drug name** in the results table.

| Results Per page: 25 Sort by: Relevance Order Columns | | | | | | | View |
|---|---|------------------------------------|--|-----------------------------------|------------------------------|---------------|------|
| Drug Name | Active Companies | Active Indications | Target-based Actions | Highest Status | Total Forecast Sales (USD M) | | |
| lebrikizumab | Filters : [0] Almirall SA; Dermira Inc | Filters : [0] Atopic dermatitis | Filters : [0] IL-13 receptor antagonist | Filters : [0] Pre-registration | 2023- 55.02 | 2024- 441.33 | |
| | | | | | 2025- 934.52 | 2026- 1400.54 | |

Consensus Industry Analyst Forecast is available on the results page and in drug reports.

- Go to **'Sales and Forecasts'** tab to view charts displaying yearly consensus forecast based on industry analysts' predictions. Values may be broken down by company and/or regions depending on their calculations.



- Click the **grid button** at the top right to display details. The next table will allow you to confirm the franchise name, evaluate individual values predicted, see the dates of those predictions and identify some of brokers' names.

Company

Region

Download

Broker Research by Company

View

| Year | Company | Franchise | Broker | Date | Value | Consensus* |
|---------------|----------------|-------------------|-------------------|-------------|--------|------------|
| 2023 | Eli Lilly & Co | Atopic dermatitis | Undisclosed 1 | 20-Jul-2023 | 32.00 | 47.14 |
| | | | Undisclosed 2 | 18-Jul-2023 | 27.00 | |
| | | | Bank Berenberg | 07-Mar-2023 | 60.00 | |
| | | | Atlantic Equities | 20-Feb-2023 | 31.00 | |
| | | | Societe Generale | 15-Feb-2023 | 100.00 | |
| | | | Leerink Swann | 16-Dec-2022 | 30.00 | |
| | | | Undisclosed 3 | 27-Sep-2022 | 50.00 | |
| Total | | | | | | 47.14 |
| 2024 | Almirall SA | Atopic dermatitis | Undisclosed 4 | 09-May-2023 | 90.11 | 56.90 |
| | Eli Lilly & Co | Atopic dermatitis | Undisclosed 1 | 20-Jul-2023 | 313.00 | 384.43 |
| | | | Undisclosed 2 | 18-Jul-2023 | 109.00 | |
| | | | Leerink Swann | 01-May-2023 | 480.00 | |
| | | | Bank Berenberg | 07-Mar-2023 | 735.00 | |
| | | | Atlantic Equities | 20-Feb-2023 | 204.00 | |
| | | | Societe Generale | 15-Feb-2023 | 350.00 | |
| Undisclosed 3 | 30-Aug-2021 | 500.00 | | | | |

You can navigate to this drug report by clicking [this link](#).

5. Sorting options in the results table will help you find the drugs with best forecast expectations in a couple of clicks.

| Results | | Per page: 25 | Sort by: | Total Forecast Sales (USD M) | 2023 | Highest to Lowest | Order Columns | View | |
|----------------------------|-----------------------------------|--------------|----------|---|--|---|---------------------------------------|--|--|
| Drug Name | | | | Relevance Last Change Date Highest Phase Drug Name Total Reported Sales 2022 (USD M) Total Forecast Sales (USD M) Added Date | Active Indications Filters : [0] | Target-based Actions Filters : [0] | Highest Status Filters : [1] Clear | Total Forecast Sales (USD M) | |
| lebrizumab | | | | | Atopic dermatitis | IL-13 receptor antagonist | Pre-registration | 2023- 55.02 2024- 441.33 2025- 934.52 2026- 1400.54 2027- 1705.95 2028- 1892.86 2029- 2066.74 2030- No data | |
| etrasimod | Everest Medicines Ltd; Pfizer Inc | | | | Alopecia areata; Atopic dermatitis; Crohns disease; Eosinophilic esophagitis; Ulcerative colitis | Sphingosine 1 phosphate phosphatase 1 stimulator; Sphingosine-1-phosphate receptor-1 modulator; | Pre-registration | 2023- 42.67 2024- 263.17 2025- 500.50 2026- 730.83 | |

'Order Columns' will help you customize your results table to display Industry Analyst Forecasts when available.

To find out what's included in your subscription, contact your Clarivate account manager or **LS Product Support**.